PAR-25-099: Planning for Product Development Strategy (R34 Clinical Trial Not Allowed)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2024.
National Institutes of Health offered grants of up to $225,000 to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. It expected to make $225,000 in total. Applications closed on February 19, 2026.
From the official notice on Grants.gov, last changed February 19, 2026. Checked November 7, 2026.
- Award ceiling$225,000
- Total funding$225,000
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeR34
- Clinical trialsNot allowed
- R34, Planning Grant. Planning a clinical trial: design, protocol and feasibility work before the trial itself. Other open R34 notices.
Application due dates, page limits and budget limits are set in the notice. Read PAR-25-099 in the NIH Guide.
Other notices with this title
| Notice | Posted | Deadline | Status |
|---|---|---|---|
| PAR-24-029 | August 14, 2023 | Closed December 29, 2024 | Closed |
Key dates
| Posted | December 30, 2024 |
|---|---|
| Deadline | February 19, 2026 |
| Archived by Grants.gov | March 21, 2026 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Is this a realistic fit?
- Past Allergy and Infectious Diseases Research awards averaged $1.6 million; this notice allows up to $225,000 per award.
- Most of the program's money (67% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The purpose of this Notice of Funding Opportunity (NOFO) is to support the development of a comprehensive and well-defined product development strategy for next-generation treatments for HIV and HIV-associated comorbidities, coinfections and complication and preventive strategies for HIV, as well as facilitating the translation of research findings into drug products that enables submission of an Investigational New Drug (IND) application to the FDA.
Who has won Allergy and Infectious Diseases Research grants before
From fiscal 2021 to 2025, Allergy and Infectious Diseases Research (93.855) awarded $22 billion across 13,282 grant awards, an average of $1.6 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Fred Hutchinson Cancer Center | Washington | 85 | $938 million |
| Duke University | North Carolina | 230 | $781 million |
| University of California, Los Angeles | California | 138 | $745 million |
| The Johns Hopkins University | Maryland | 321 | $668 million |
| Emory University | Georgia | 282 | $650 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is PAR-25-099 still open?
No. It closed on February 19, 2026.
Who can apply for Planning for Product Development Strategy (R34 Clinical Trial Not Allowed)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Planning for Product Development Strategy (R34 Clinical Trial Not Allowed)?
Closed February 19, 2026. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $225,000 each. About $225,000 in total.
Who has won Allergy and Infectious Diseases Research grants before?
The largest recipients over five fiscal years were Fred Hutchinson Cancer Center, Duke University, University of California, Los Angeles. The program made 13,282 awards worth $22 billion in that time.
Similar open grants
- Feasibility Clinical Trials of Mind and Body Interventions for NCCIH High Priority Research Topics (R34 Clinical Trial Required)
- Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R34 Clinical Trial Optional)
- Intervention Research to Improve Native American Health (R34 Clinical Trial Optional)
- Innovative Research to Improve Native Hawaiian and Pacific Islander (NHPI) Health Outcomes (R34 - Clinical Trial Optional)
- NHLBI Clinical Trial Pilot Studies (R34 Clinical Trial Optional)
- Change of Recipient Organization (Type 7 Parent Clinical Trial Optional)